Is Bloom Energy The Best Stock to Buy Now?
Shares of energy startup Bloom Energy (NYSE:BE) have advanced by…
Sell
39
MLYS Quote, Financials, Valuation and Earnings
Last price:
$36.85
Seasonality move
:
41.51%
Day range:
$36.16 - $38.40
52-week range:
$8.24 - $47.65
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
5.06x
Volume:
6.2M
Avg. volume:
1.9M
1-year change:
211.33%
Market cap:
$2.9B
Revenue:
--
EPS (TTM):
-$2.96
Analysts' Opinion
-
Consensus RatingMineralys Therapeutics, Inc. has received a consensus rating of Buy. The company's average rating is a Buy based on 8 Buy ratings, 1 Hold rating, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $50.88, Mineralys Therapeutics, Inc. has an estimated upside of 35.76% from its current price of $36.83.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $42.00 representing -14.04% downside risk from its current price of $36.83.
Fair Value
-
According to the consensus of 9 analysts, Mineralys Therapeutics, Inc. has 35.76% upside to fair value with a price target of $50.88 per share.
MLYS vs. S&P 500
-
Over the past 5 trading days, Mineralys Therapeutics, Inc. has underperformed the S&P 500 by -0.29% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Mineralys Therapeutics, Inc. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Mineralys Therapeutics, Inc. has grown year-over-year revenues for 0 quarters straight. In the most recent quarter Mineralys Therapeutics, Inc. reported revenues of --.
Earnings Growth
-
Mineralys Therapeutics, Inc. has grown year-over-year earnings for 2 quarters straight. In the most recent quarter Mineralys Therapeutics, Inc. reported earnings per share of -$0.52.
Enterprise value:
2.3B
EV / Invested capital:
4.03x
Price / LTM sales:
--
EV / EBIT:
--
EV / Revenue:
--
PEG ratio (5yr expected):
-0.41x
EV / Free cash flow:
-13.54x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
-$61K
Return On Assets:
-48.55%
Net Income Margin (TTM):
--
Return On Equity:
-51.62%
Return On Invested Capital:
-51.62%
Operating Margin:
--
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Income Statement | ||||||
| Revenue | -- | -- | -- | -- | -- | |
| Gross Profit | -- | -$28K | -$61K | -$11K | -$15K | |
| Operating Income | -$67M | -$168.3M | -$184.1M | -$60.1M | -$41.1M | |
| EBITDA | -$67M | -$168.3M | -$184M | -$60.1M | -$41.1M | |
| Diluted EPS | -$1.38 | -$3.27 | -$2.96 | -$1.13 | -$0.52 | |
| Period Ending | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2025-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | -- | $121.9M | $265.4M | $267.7M | $599.8M | |
| Total Assets | -- | $122.5M | $277.6M | $268.3M | $599.9M | |
| Current Liabilities | -- | $7.2M | $13.5M | $31.3M | $23.5M | |
| Total Liabilities | -- | $7.2M | $13.5M | $31.3M | $23.5M | |
| Total Equity | -- | $115.2M | $264M | $236.9M | $576.4M | |
| Total Debt | -- | -- | -- | -- | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$62.4M | -$128.5M | -$171.4M | -$50.2M | -$28.9M | |
| Cash From Investing | -$102.4M | $23.3M | -$202.7M | $79.6M | -$150.5M | |
| Cash From Financing | $202.1M | $116.1M | $494.4M | -$1K | $295.2M | |
| Free Cash Flow | -$62.4M | -$128.5M | -$171.4M | -$50.2M | -$28.9M | |
MLYS
Sector
Market Cap
$2.9B
$27.9M
Price % of 52-Week High
77.29%
51.04%
Dividend Yield
0%
0%
Shareholder Yield
-16.51%
-1.49%
1-Year Price Total Return
211.33%
-16.66%
Beta (5-Year)
--
0.516
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Buy
Level
$36.51
200-day SMA
Buy
Level
$24.23
Bollinger Bands (100)
Buy
Level
23.08 - 44.84
Chaikin Money Flow
Buy
Level
6.5M
20-day SMA
Sell
Level
$38.83
Relative Strength Index (RSI14)
Sell
Level
40.71
ADX Line
Sell
Level
21.28
Williams %R
Neutral
Level
-78.1901
50-day SMA
Sell
Level
$40.75
MACD (12, 26)
Sell
Level
-1.28
25-day Aroon Oscillator
Buy
Level
4
On Balance Volume
Neutral
Level
29.7M
Financial Scores
Buy
Altman Z-Score
(Annual)
Level (21.0961)
Sell
CA Score
(Annual)
Level (-2.2138)
--
Beneish M-Score
(Annual)
Level (--)
Buy
Momentum Score
Level (10)
Sell
Ohlson Score
Level (21.1442)
--
Piotroski F Score
(Annual)
Level (--)
Sell
Quality Ratio Score
Level (2)
Buy
Fundamental Score
Level (3)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Mineralys Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on developing medicines to target diseases driven by abnormally elevated aldosterone. Its clinical-stage product candidate, lorundrostat, is a proprietary, orally administered, highly selective aldosterone synthase inhibitor that are initially developing for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone, including hypertension and chronic kidney disease. The company was founded by Brian Taylor Slingsby on May 31, 2019 and is headquartered in Radnor, PA.
Stock Forecast FAQ
In the current month, MLYS has received 8 Buy ratings 1 Hold ratings, and 0 Sell ratings. The MLYS average analyst price target in the past 3 months is $50.88.
-
Where Will Mineralys Therapeutics, Inc. Stock Be In 1 Year?
According to analysts, the consensus estimate is that Mineralys Therapeutics, Inc. share price will rise to $50.88 per share over the next 12 months.
-
What Do Analysts Say About Mineralys Therapeutics, Inc.?
Analysts are divided on their view about Mineralys Therapeutics, Inc. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Mineralys Therapeutics, Inc. is a Sell and believe this share price will drop from its current level to $42.00.
-
What Is Mineralys Therapeutics, Inc.'s Price Target?
The price target for Mineralys Therapeutics, Inc. over the next 1-year time period is forecast to be $50.88 according to 9 Wall Street analysts, 8 of them rate the stock a Buy, 0 rate the stock a Sell, and 1 analyst rates the stock a Hold.
-
Is MLYS A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Mineralys Therapeutics, Inc. is a Buy. 8 of 9 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of MLYS?
You can purchase shares of Mineralys Therapeutics, Inc. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Mineralys Therapeutics, Inc. shares.
-
What Is The Mineralys Therapeutics, Inc. Share Price Today?
Mineralys Therapeutics, Inc. was last trading at $36.85 per share. This represents the most recent stock quote for Mineralys Therapeutics, Inc.. Yesterday, Mineralys Therapeutics, Inc. closed at $36.83 per share.
-
How To Buy Mineralys Therapeutics, Inc. Stock Online?
In order to purchase Mineralys Therapeutics, Inc. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Get MLYS Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
MLYS
Sector
P/E ratio
--
23.85x
PEG ratio
-0.41x
-0.01x
P/B ratio
5.06x
1.81x
Price / LTM sales
--
1.58x
Growth Metrics
MLYS
Sector
Revenue growth
--
4.62%
Earnings growth
53.74%
10.5%
Revenue (5-year growth)
--
6.5%
Earnings forecast
-$0.61
-$0.21
Profitability
MLYS
Sector
Profitability FY 2024
-$43K
$3.6M
Return on invested capital
-51.62%
-31.87%
Return on assets
-48.55%
-28.18%
Return on equity
-51.62%
-37.63%
Earnings Date
Last Earnings Date
Nov
10
Next Earnings Date
Feb
12
Estimated Next Earnings Date
Feb
9
Balance Sheet
MLYS
Sector
Total cash
$593.6M
$26.4M
Short term investments
$84.1M
$25.7M
Total assets
$205.9M
$76.9M
Long term debt
--
$3.4M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Berkshire Hathaway Stock Undervalued?
Berkshire Hathaway (NYSE:BRK.A,BRK.B) has undershot the market this year, returning…
Is Oracle Stock Undervalued?
Shares of Oracle (NYSE:ORCL) rocketed higher earlier this year when…
Stock Ideas
Buy
54
Is NVDA Stock a Buy?
Market Cap: $4.4T
P/E Ratio: 62x
Buy
53
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 37x
Buy
57
Is GOOG Stock a Buy?
Market Cap: $3.7T
P/E Ratio: 38x
Alerts
Sell
1
LW alert for Dec 20
Lamb Weston Holdings, Inc. [LW] is down 25.96% over the past day.
Buy
54
BMRN alert for Dec 20
BioMarin Pharmaceutical, Inc. [BMRN] is up 17.79% over the past day.
Buy
82
RKLB alert for Dec 20
Rocket Lab Corp. [RKLB] is up 17.72% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
